Effect of systemic bisphosphonate administration on patients with periodontal disease: a systematic review and meta-analysis protocol

Abstract

IntroductionPeriodontal disease is a chronic oral infectious disease affecting adults worldwide as well as a lifestyle-related disease related to diabetes. Bisphosphonate is a drug often taken by patients with osteoporosis; however, it reportedly can cause jawbone necrosis. Due to its mechanism of action on bone tissue, bisphosphonate has been used topically on periodontal tissue to treat periodontal disease. However, the long-term systemic effects of bisphosphonates on periodontal tissues are unclear. This paper describes a protocol evaluating the effects of systemic bisphosphonate administration to prevent periodontal tissue destruction in patients with periodontal disease. No systematic review has attempted to summarise the evidence for systemic bisphosphonates in periodontal therapy. The results of the proposed systematic review will inform the practice and design of future clinical trials.Methods and analysisThis paper describes a protocol for a systematic review of the relevant published analytic research using an aggregative thematic approach according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols guidelines. Two authors will perform a comprehensive search for studies on Medline/PubMed, Scopus, Embase, LILACS and the Cochrane Central Register of Controlled Trials databases. Abstract screening, full-text screening and data extraction will be performed independently by two authors. A meta-analysis will be conducted as appropriate.Ethics and disseminationThe protocol of this systematic review will be provided in a peer-reviewed journal. Formal ethics approval is not necessary because researchers will not identify individuals in the report.PROSPERO registration numberCRD42020212698 (http://www.crd.york.ac.uk/PROSPERO/).

Does adjunction of Melaleuca alternifolia to periodontal treatment protocol improve clinical outcome?

“…Periodontal disease (PeDi) is a complex multifactorial inflammatory oral disease, caused by anaerobic periodontopathic bacteria, categorised by loss of clinical attachment and destruction of periodontal tissues. 1 Following diagnosis confirmation, PeDi is categorised by the process of staging and grading using specific decision-making algorithms to confirm the diagnosis, assess risks, and complexity management of PeDi. 2 Conventional non-surgical periodontal therapy to manage PeDi involves mechanical Lana O'Brien is a third year student at the University of the Highlands and Islands (UHI).…”

Anticorpo anti-RANKL como modulador da perda óssea alveolar em periodontite experimental induzida em animais: uma revisão sistemática

“…Dentre os agentes de modulação da resposta imune do hospedeiro sobre a periodontite, elencam-se atualmente, como possíveis alvos de manejo adjunto da doença, a inibição do sistema complemento (31), anti-inflamatórios não esteroidais (AINEs) (32), quimiocinas para células T (33), agentes promotores de resolução da inflamação (34), bisfosfonatos (35), inibidores de metaloproteinase da matriz (MMP) (36), antagonistas de RANK (37), probióticos (38), terapias anti-citocinas e imunizantes contra patobiontes (6).…”